Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision

PLoS Computational Biology

Volumn 9, Issue 10, 2013, Pages

  Grieco, Luca ^a,b,c,d,e,f   Calzone, Laurence ^f,g,h   Bernard Pierrot, Isabelle ^d,f   Radvanyi, François ^d,f   Kahn Perlès, Brigitte ^b   Thieffry, Denis ^b,c,d,e,i  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Aix Marseille university   (France)

^c ECOLE NORMALE SUPÉRIEURE   (France)

^d CNRS   (France)

^e INSERM   (France)

^f INSTITUT CURIE   (France)

^g INSERM U900   (France)

^h PSL RESEARCH UNIVERSITY   (France)

ⁱ INRIA ROCQUENCOURT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CELL SIGNALING; DEREGULATION; DISEASES;

CANCER CELLS; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE DECISION; CELL SURVIVAL; CELLULAR PROCESS; INTEGRATIVE MODELING; LOGICAL MODELS; MITOGEN-ACTIVATED PROTEIN KINASE; SIGNALLING PATHWAYS;

CELL DEATH;

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE;

ALGORITHM; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL FATE; CELL INTERACTION; CELL PROLIFERATION; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; FEEDBACK SYSTEM; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION;

ALGORITHMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; INTRACELLULAR SPACE; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; PROTEIN INTERACTION MAPS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SOFTWARE; URINARY BLADDER NEOPLASMS;

EID: 84887303651     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003286     Document Type: Article

References (89)

1. Krishna M, Narang H, (2008) The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cellular and Molecular Life Sciences 65: 3525-3544 doi:10.1007/s00018-008-8170-7.
2. Junttila MR, Li S-P, Westermarck J, (2007) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. The FASEB Journal 22: 954-965 doi:10.1096/fj.06-7859rev.
3. Shen YH, (2003) Cross-talk between JNK/SAPK and ERK/MAPK Pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. Journal of Biological Chemistry 278: 26715-26721 doi:10.1074/jbc.M303264200.
4. Zehorai E, Yao Z, Plotnikov A, Seger R, (2010) The subcellular localization of MEK and ERK-A novel nuclear translocation signal (NTS) paves a way to the nucleus. Molecular and Cellular Endocrinology 314: 213-220 doi:10.1016/j.mce.2009.04.008.
5. Owens DM, Keyse SM, (2007) Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213 doi:10.1038/sj.onc.1210412.
6. Morrison DK, Davis RJ, (2003) Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annual Review of Cell and Developmental Biology 19: 91-118 doi:10.1146/annurev.cellbio.19.111401.091942.
7. Kyriakis JM, Avruch J, (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiological reviews 81: 807-869.
8. Roux PP, Blenis J, (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and molecular biology reviews 68: 320-344.
9. Kolch W, Calder M, Gilbert D, (2005) When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Letters 579: 1891-1895 doi:10.1016/j.febslet.2005.02.002.
10. Plotnikov A, Zehorai E, Procaccia S, Seger R, (2011) The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochimica et Biophysica Acta (BBA)- Molecular Cell Research 1813: 1619-1633 doi:10.1016/j.bbamcr.2010.12.012.
11. Dhillon AS, Hagan S, Rath O, Kolch W, (2007) MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290 doi:10.1038/sj.onc.1210421.
12. Wagner EF, Nebreda ÁR, (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer 9: 537-549 doi:10.1038/nrc2694.
13. Halilovic E, Solit DB, (2008) Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current Opinion in Pharmacology 8: 419-426 doi:10.1016/j.coph.2008.06.014.
14. Santarpia L, Lippman SM, El-Naggar AK, (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16: 103-119 doi:10.1517/14728222.2011.645805.
15. Zachos I, Konstantinopoulos PA, Tzortzis V, Gravas S, Karatzas A, et al. (2010) Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opinion on Investigational Drugs 19: 875-887 doi:10.1517/13543784.2010.496450.
16. Yong H-Y, Koh M-S, Moon A, (2009) The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs 18: 1893-1905 doi:10.1517/13543780903321490.
17. Sullivan RJ, Atkins MB, (2010) Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opinion on Investigational Drugs 19: 1205-1216 doi:10.1517/13543784.2010.504709.
18. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, et al. (2009) Chapter 1 Ras Signaling and Therapies. Advances in Cancer Research. Elsevier, Vol. 102. pp. 1-17. Available: http://linkinghub.elsevier.com/retrieve/pii/S0065230X09020016.
19. Poulikakos PI, Solit DB, (2011) Resistance to MEK inhibitors: should we co-target upstream? Science Signalling 4: pe16.
20. Haagenson KK, Wu GS, (2010) The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer and Metastasis Reviews 29: 143-149 doi:10.1007/s10555-010-9208-5.
21. Chapman MS, Miner JN, (2011) Novel mitogen-activated protein kinase kinase inhibitors. Expert Opinion on Investigational Drugs 20: 209-220 doi:10.1517/13543784.2011.548803.
22. Cakir M, Grossman AB, (2009) Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opinion on Therapeutic Targets 13: 1121-1134 doi:10.1517/14728220903170675.
23. Montagut C, Settleman J, (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Letters 283: 125-134 doi:10.1016/j.canlet.2009.01.022.
24. Inamdar GS, Madhunapantula SV, Robertson GP, (2010) Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochemical Pharmacology 80: 624-637 doi:10.1016/j.bcp.2010.04.029.
25. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, et al. (2005) Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochemical Journal 392: 249 doi:10.1042/BJ20050908.
26. Huang CY, Ferrell JE, (1996) Ultrasensitivity in the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences 93: 10078-10083.
27. Kholodenko BN, (2001) Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. European Journal of Biochemistry 267: 1583-1588.
28. Levchenko A, Bruck J, Sternberg PW, (2000) Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proceedings of the National Academy of Sciences 97: 5818-5823.
29. Markevich NI, (2004) Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. The Journal of Cell Biology 164: 353-359 doi:10.1083/jcb.200308060.
30. Legewie S, Schoeberl B, Blüthgen N, Herzel H, (2007) Competing Docking Interactions can Bring About Bistability in the MAPK Cascade. Biophysical Journal 93: 2279-2288 doi:10.1529/biophysj.107.109132.
31. Smolen P, Baxter DA, Byrne JH, (2007) Bistable MAP kinase activity: a plausible mechanism contributing to maintenance of late long-term potentiation. AJP: Cell Physiology 294: C503-C515 doi:10.1152/ajpcell.00447.2007.
32. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, et al. (2010) The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Science Signalling 3: ra90.
33. Brightman FA, Fell DA, (2000) Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells. FEBS letters 482: 169-174.
34. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G, (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature biotechnology 20: 370-375.
35. Hatakeyama M, Kimura S, Naka T, Kawasaki T, Yumoto N, et al. (2003) A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochemical Journal 373: 451.
36. Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, et al. (2005) Control of MAPK signalling: from complexity to what really matters. Oncogene 24: 5533-5542.
37. Sasagawa S, Ozaki Y, Fujita K, Kuroda S, (2005) Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nature Cell Biology 7: 365-373 doi:10.1038/ncb1233.
38. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, et al. (2009) Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Systems Biology 3: 100 doi:10.1186/1752-0509-3-100.
39. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, et al. (2009) Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Molecular Systems Biology 5: 239 Available: http://www.nature.com/doifinder/10.1038/msb.2008.74.
40. Bagheri N, Shiina M, Lauffenburger DA, Korn WM, (2011) A Dynamical Systems Model for Combinatorial Cancer Therapy Enhances Oncolytic Adenovirus Efficacy by MEK-Inhibition. PLoS Computational Biology 7: e1001085 doi:10.1371/journal.pcbi.1001085.
41. Handorf T, Klipp E, (2011) Modeling mechanistic biological networks: An advanced Boolean approach. Bioinformatics 28: 557-563 doi:10.1093/bioinformatics/btr697.
42. Finch AR, Caunt CJ, Perrett RM, Tsaneva-Atanasova K, McArdle CA, (2012) Dual specificity phosphatases 10 and 16 are positive regulators of EGF-stimulated ERK activity: Indirect regulation of ERK signals by JNK/p38 selective MAPK phosphatases. Cellular Signalling 24: 1002-1011 doi:10.1016/j.cellsig.2011.12.021.
43. Samaga R, Saez-Rodriguez J, Alexopoulos LG, Sorger PK, Klamt S, (2009) The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data. PLoS Computational Biology 5: e1000438 doi:10.1371/journal.pcbi.1000438.
44. Oda K, Matsuoka Y, Funahashi A, Kitano H, (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology 1: E1-E17 doi:10.1038/msb4100014.
45. Poltz R, Naumann M, (2012) Dynamics of p53 and NF-kappaB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention. BMC Systems Biology 6: 125.
46. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
47. Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, et al. (2012) Deregulation of Rab and Rab Effector Genes in Bladder Cancer. PLoS One 7: e39469 doi:10.1371/journal.pone.0039469.
48. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, de Medina SGD, et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. The American journal of pathology 158: 1955.
49. Williams SV, Hurst CD, Knowles MA, (2012) Oncogenic FGFR3 gene fusions in bladder cancer. Human Molecular Genetics 22 (4) (): 795-803 Available: http://www.hmg.oxfordjournals.org/cgi/doi/10.1093/hmg/dds486.
50. Mitra AP, Cote RJ, (2009) Molecular Pathogenesis and Diagnostics of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease 4: 251-285 doi:10.1146/annurev.pathol.4.110807.092230.
51. Mitra AP, Datar RH, Cote RJ, (2006) Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification. Journal of Clinical Oncology 24: 5552-5564 doi:10.1200/JCO.2006.08.2073.
52. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
53. Funahashi A, Morohashi M, Kitano H, Tanimura N, (2003) CellDesigner: a process diagram editor for gene-regulatory and biochemical networks. BIOSILICO 1: 159-162 doi:10.1016/S1478-5382(03)02370-9.
54. Kitano H, Funahashi A, Matsuoka Y, Oda K, (2005) Using process diagrams for the graphical representation of biological networks. Nature Biotechnology 23: 961-966 doi:10.1038/nbt1111.
55. Funahashi A, Matsuoka Y, Jouraku A, Morohashi M, Kikuchi N, et al. (2008) CellDesigner 3.5: A Versatile Modeling Tool for Biochemical Networks. Proceedings of the IEEE 96: 1254-1265 doi:10.1109/JPROC.2008.925458.
56. Naldi A, Berenguier D, Fauré A, Lopez F, Thieffry D, et al. (2009) Logical modelling of regulatory networks with GINsim 2.3. Biosystems 97: 134-139 doi:10.1016/j.biosystems.2009.04.008.
57. Chaouiya C, Naldi A, Thieffry D, (2012) Logical Modelling of Gene Regulatory Networks with GINsim. Methods in Molecular Biology 804: 463-479 Available: http://www.springerlink.com/index/10.1007/978-1-61779-361-5_23.
58. Thomas R, (1991) Regulatory networks seen as asynchronous automata: A logical description. Journal of Theoretical Biology 153: 1-23 doi:10.1016/S0022-5193(05)80350-9.
59. Thomas R, Thieffry D, Kaufman M, (1995) Dynamical behaviour of biological regulatory networks-I. Biological role of feedback loops and practical use of the concept of the loop-characteristic state. Bulletin of Mathematical Biology 57: 247-276.
60. Chaouiya C, Remy E, Mossé B, Thieffry D, (2003) Qualitative analysis of regulatory graphs: a computational tool based on a discrete formal framework. Positive Systems pp. 830-832.
61. Faure A, Naldi A, Chaouiya C, Thieffry D, (2006) Dynamical analysis of a generic Boolean model for the control of the mammalian cell cycle. Bioinformatics 22: e124-e131 doi:10.1093/bioinformatics/btl210.
62. Naldi A, Thieffry D, Chaouiya C, (2007) Decision diagrams for the representation and analysis of logical models of genetic networks. Computational Methods in Systems Biology pp. 233-247 Available: http://www.springerlink.com/index/ww3402468t532578.pdf.
63. Naldi A, Remy E, Thieffry D, Chaouiya C, (2011) Dynamically consistent reduction of logical regulatory graphs. Theoretical Computer Science 412: 2207-2218 doi:10.1016/j.tcs.2010.10.021.
64. Bérenguier D, Chaouiya C, Monteiro PT, Naldi A, Remy E, et al. (2013) Dynamical modeling and analysis of large cellular regulatory networks. Chaos 23: 025114 doi: 10.1063/1.4809783.
65. Thomas R, (1981) On the relation between the logical structure of systems and their ability to generate multiple steady states or sustained oscillations. Springer Series in Synergetics 9: 180-193.
66. Remy É, Ruet P, Thieffry D, (2008) Graphic requirements for multistability and attractive cycles in a Boolean dynamical framework. Advances in Applied Mathematics 41: 335-350 doi:10.1016/j.aam.2007.11.003.
67. Thieffry D, (2007) Dynamical roles of biological regulatory circuits. Briefings in Bioinformatics 8: 220-225 doi:10.1093/bib/bbm028.
68. Weinberg RA (2007) The Biology of cancer. New York: Garland Science.
69. Takekawa M, Kubota Y, Nakamura T, Ichikawa K, (2011) Regulation of stress-activated MAP kinase pathways during cell fate decisions. Nagoya journal of medical science 73: 1-14.
70. Heldin C-H, Landström M, Moustakas A, (2009) Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Current Opinion in Cell Biology 21: 166-176 doi:10.1016/j.ceb.2009.01.021.
71. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, et al. (2000) MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19: 5406-5412 doi:10.1038/sj.onc.1203918.
72. Sears RC, (2002) Signaling Networks That Link Cell Proliferation and Cell Fate. Journal of Biological Chemistry 277: 11617-11620 doi:10.1074/jbc.R100063200.
73. Schulz WA, (2006) Understanding urothelial carcinoma through cancer pathways. International Journal of Cancer 119: 1513-1518 doi:10.1002/ijc.21852.
74. Cho JY, (2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proceedings of the National Academy of Sciences 101: 609-614 doi:10.1073/pnas.2237184100.
75. Schlessinger J, (2004) Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors. Science 306: 1506-1507 doi:10.1126/science.1105396.
76. Cochet C, Gill GN, Meisenhelder J, Cooper JA, Hunter T, (1984) C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity. Journal of Biological Chemistry 259: 2553-2558.
77. Li L, Chen SF, Liu Y, (2009) MAP kinase phosphatase-1, a critical negative regulator of the innate immune response. International journal of clinical and experimental medicine 2: 48.
78. Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, et al. (2010) Mathematical Modelling of Cell-Fate Decision in Response to Death Receptor Engagement. PLoS Computational Biology 6: e1000702 doi:10.1371/journal.pcbi.1000702.
79. Foldynova-Trantirkova S, Wilcox WR, Krejci P, (2012) Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Human Mutation 33: 29-41 doi:10.1002/humu.21636.
80. Priore R, Dailey L, Basilico C, (2006) Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J Cell Physiol 207: 800-808 doi:10.1002/jcp.20620.
81. Stoll G, Viara E, Barillot E, Calzone L, (2012) Continuous time Boolean modeling for biological signaling: application of Gillespie algorithm. BMC Systems Biology 6: 116 doi:10.1186/1752-0509-6-116.
82. Roovers K, Assoian RK, (2000) Integrating the MAP kinase signal into the G 1 phase cell cycle machinery. Bioessays 22: 818-826.
83. Blinov ML, Faeder JR, Goldstein B, Hlavacek WS, (2006) A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystems 83: 136-151 doi:10.1016/j.biosystems.2005.06.014.
84. Feret J, Danos V, Krivine J, Harmer R, Fontana W, (2009) Internal coarse-graining of molecular systems. Proceedings of the National Academy of Sciences of the United States of America 106: 6453-6458 doi: 10.1073/pnas.0809908106.
85. Fages F, Soliman S, (2008) From reaction models to influence graphs and back: a theorem. Formal Methods in Systems Biology 5054: 90-102.
86. Sharp S, Workman P (2006) Inhibitors of the HSP90 Molecular Chaperone: Current Status. Advances in Cancer Research. Elsevier, Vol. 95. pp. 323-348. Available: http://linkinghub.elsevier.com/retrieve/pii/S0065230X0695009X.
87. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, et al. (1998) Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. Journal of the National Cancer Institute 90: 1072-1079.
88. Kennedy NJ, Davis RJ, (2003) Role of JNK in tumor development. Cell Cycle 2: 199-201.
89. Schramek H, (2002) MAP kinases: from intracellular signals to physiology and disease. Physiology 17: 62-67.